MA40873A - Alcools trifluorométhylés utilisés comme modulateurs de roryt - Google Patents
Alcools trifluorométhylés utilisés comme modulateurs de rorytInfo
- Publication number
- MA40873A MA40873A MA040873A MA40873A MA40873A MA 40873 A MA40873 A MA 40873A MA 040873 A MA040873 A MA 040873A MA 40873 A MA40873 A MA 40873A MA 40873 A MA40873 A MA 40873A
- Authority
- MA
- Morocco
- Prior art keywords
- sup
- trifluoromethylated
- alcohols used
- relates
- roryt modulators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Otolaryngology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
<!--startfragment-->la présente invention concerne des composés de formule (i), dans laquelle x, a<sup>1</sup>, a<sup>2</sup>, a<sup>3</sup>, a<sup>4</sup>, r<sup>1</sup>, r<sup>2</sup> et r<sup>3</sup> sont tels que définis dans la description. L'invention concerne également un procédé pour traiter ou atténuer un syndrome, un trouble ou une maladie, ledit syndrome, ledit trouble ou ladite maladie étant la polyarthrite rhumatoïde ou le psoriasis. L'invention concerne également un procédé pour moduler l'activité de rorγt chez un mammifère par administration d'une quantité thérapeutiquement efficace d'au moins un composé de la revendication 1.<!--endfragment-->
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462072563P | 2014-10-30 | 2014-10-30 | |
PCT/US2015/058193 WO2016069974A1 (fr) | 2014-10-30 | 2015-10-30 | Alcools trifluorométhylés utilisés comme modulateurs de roryt |
Publications (2)
Publication Number | Publication Date |
---|---|
MA40873A true MA40873A (fr) | 2017-09-05 |
MA40873B1 MA40873B1 (fr) | 2019-07-31 |
Family
ID=54754732
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA40873A MA40873B1 (fr) | 2014-10-30 | 2015-10-29 | Alcools trifluorométhylés utilisés comme modulateurs de roryt |
Country Status (40)
Country | Link |
---|---|
US (2) | US9850236B2 (fr) |
EP (2) | EP3212643B1 (fr) |
JP (3) | JP6998204B2 (fr) |
KR (2) | KR20170127580A (fr) |
CN (3) | CN107827841A (fr) |
AR (2) | AR102480A1 (fr) |
AU (2) | AU2015339087B2 (fr) |
BR (2) | BR112017008816A2 (fr) |
CA (1) | CA2965512C (fr) |
CL (3) | CL2017001042A1 (fr) |
CO (1) | CO2017005014A2 (fr) |
CR (2) | CR20170166A (fr) |
CY (1) | CY1121716T1 (fr) |
DK (1) | DK3212643T3 (fr) |
EA (2) | EA033699B1 (fr) |
EC (1) | ECSP17033054A (fr) |
ES (2) | ES2724556T3 (fr) |
GT (1) | GT201700090A (fr) |
HK (1) | HK1258212A1 (fr) |
HR (1) | HRP20190900T1 (fr) |
HU (1) | HUE043624T2 (fr) |
IL (2) | IL251865A0 (fr) |
JO (2) | JOP20200117A1 (fr) |
LT (1) | LT3212643T (fr) |
MA (1) | MA40873B1 (fr) |
ME (1) | ME03426B (fr) |
MX (2) | MX367912B (fr) |
PE (2) | PE20171649A1 (fr) |
PH (2) | PH12017500800A1 (fr) |
PL (1) | PL3212643T3 (fr) |
PT (1) | PT3212643T (fr) |
RS (1) | RS58613B1 (fr) |
SG (2) | SG11201703323PA (fr) |
SI (1) | SI3212643T1 (fr) |
SV (1) | SV2017005429A (fr) |
TR (1) | TR201907763T4 (fr) |
TW (2) | TWI667230B (fr) |
UY (2) | UY36377A (fr) |
WO (1) | WO2016069974A1 (fr) |
ZA (3) | ZA201703679B (fr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201803869A (zh) * | 2016-04-27 | 2018-02-01 | 健生藥品公司 | 作為RORγT調節劑之6-胺基吡啶-3-基噻唑 |
EP3765009A4 (fr) * | 2018-03-12 | 2021-11-10 | Escalier Biosciences, BV | Modulateurs de ror-gamma bicycliques |
US11242350B2 (en) | 2018-03-12 | 2022-02-08 | Escalier Biosciences B.V. | Spirocyclic ROR-gamma modulators |
US10975037B2 (en) | 2018-06-18 | 2021-04-13 | Janssen Pharmaceutica Nv | Phenyl substituted pyrazoles as modulators of RORγt |
ES2928246T3 (es) | 2018-06-18 | 2022-11-16 | Janssen Pharmaceutica Nv | 6-aminopiridin-3-il pirazoles como moduladores de RORyt |
CN112334450A (zh) * | 2018-06-18 | 2021-02-05 | 詹森药业有限公司 | 作为RORγt的调节剂的苯基和吡啶基取代的咪唑 |
CA3103932A1 (fr) | 2018-06-18 | 2019-12-26 | Janssen Pharmaceutica Nv | Pyridinyl-pyrazoles utilises utilises comme modulateurs de roryt |
WO2023232870A1 (fr) | 2022-05-31 | 2023-12-07 | Immunic Ag | Modulateurs de rorg/rorgt pour le traitement d'infections virales de type covid-19 |
WO2024089216A1 (fr) | 2022-10-27 | 2024-05-02 | Syngenta Crop Protection Ag | Nouveaux composés hétéroaryl-carboxamides contenant du soufre |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL91418A (en) | 1988-09-01 | 1997-11-20 | Rhone Poulenc Agrochimie | (hetero) cyclic amide derivatives, process for their preparation and fungicidal compositions containing them |
EP1125932A3 (fr) | 1994-07-27 | 2001-08-29 | G.D. Searle & Co. | Thiazoles substitués destinés au traitement de l'inflammation |
CN100540538C (zh) | 2001-04-16 | 2009-09-16 | 田边三菱制药株式会社 | 高传导率钙-活化k通道开启剂 |
KR100922538B1 (ko) | 2001-08-13 | 2009-10-21 | 얀센 파마슈티카 엔.브이. | 2,4,5-삼치환된 티아졸릴 유도체 및 그의 항염증성 활성 |
SA04250288B1 (ar) * | 2003-09-19 | 2008-07-19 | سولفاي فارماسوتيكالز بي . في | مشتقات ثيازول thiazole كمعدلات لمستقبل المكونات الكيميائية للقنب cannabinoid |
WO2006124687A1 (fr) | 2005-05-12 | 2006-11-23 | University Of Medicine And Dentistry Of New Jersey | Agents selectifs en fonction du sous-type de recepteurs d'opiates |
GB0518237D0 (en) * | 2005-09-07 | 2005-10-19 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
TWI444370B (zh) | 2006-01-25 | 2014-07-11 | Synta Pharmaceuticals Corp | 用於發炎及免疫相關用途之噻唑及噻二唑化合物 |
WO2008064317A1 (fr) | 2006-11-22 | 2008-05-29 | University Of Medicine And Dentistry Of New Jersey | Composés actifs de récepteurs opioïdes lipophiles |
WO2008064318A2 (fr) | 2006-11-22 | 2008-05-29 | University Of Medicine And Dentistry Of New Jersey | Composés actifs de récepteurs opioïdes périphériques |
US20090069288A1 (en) | 2007-07-16 | 2009-03-12 | Breinlinger Eric C | Novel therapeutic compounds |
ES2579085T3 (es) | 2008-07-17 | 2016-08-04 | Bayer Cropscience Ag | Compuestos heterocíclicos como pesticidas |
CA2758072A1 (fr) * | 2009-04-08 | 2010-10-14 | Idenix Pharmaceuticals, Inc. | Inhibiteurs macrocycliques de la serine protease |
AR079022A1 (es) | 2009-11-02 | 2011-12-21 | Sanofi Aventis | Derivados de acido carboxilico ciclico sustituidos con acilamino, su uso como productos farmaceuticos, composicion farmaceutica y metodo de preparacion |
EP2368886A1 (fr) * | 2010-03-01 | 2011-09-28 | Phenex Pharmaceuticals AG | Nouveaux composés pour la modulation d'activité de récepteur-gamma orphelin (gamme ROR, NR1F3) associée au RAR de récepteur nucléaire orphelin et pour le traitement des maladies chroniques et maladies auto-immunes |
HUE040420T2 (hu) | 2010-03-11 | 2019-03-28 | Univ New York | Amidvegyületek, mint RORyT modulátorok és felhasználásuk |
WO2011112264A1 (fr) | 2010-03-11 | 2011-09-15 | New York University | Composés en tant que modulateurs de rorϒt et leurs utilisations |
WO2011115892A1 (fr) | 2010-03-15 | 2011-09-22 | Griffin Patrick R | Modulateurs des récepteurs orphelins liés au récepteur de l'acide rétinoïque |
WO2012027965A1 (fr) | 2010-09-01 | 2012-03-08 | Glaxo Group Limited | Nouveaux composés |
WO2012074547A2 (fr) | 2010-11-29 | 2012-06-07 | New York University | COMPOSÉS STÉROÏDES COMME MODULATEURS DE RORγT ET LEURS UTILISATIONS |
WO2012090995A1 (fr) | 2010-12-28 | 2012-07-05 | ライオン株式会社 | Procédé pour évaluer l'état d'une cavité buccale, et dispositif, appareil et programme d'analyse associés |
WO2012129491A1 (fr) | 2011-03-24 | 2012-09-27 | Abbott Laboratories | Modulateurs de trpv3 |
US9586928B2 (en) | 2011-05-16 | 2017-03-07 | The Scripps Research Institute | Modulators of the nuclear hormone receptor ROR |
US9156837B2 (en) | 2011-07-29 | 2015-10-13 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
RU2014113926A (ru) | 2011-09-09 | 2015-10-20 | Нью Йорк Юниверсити | АМИДОСОЕДИНЕНИЯ В КАЧЕСТВЕ RORγT МОДУЛЯТОРОВ И ИХ ПРИМЕНЕНИЕ |
GB201116641D0 (en) * | 2011-09-27 | 2011-11-09 | Glaxo Group Ltd | Novel compounds |
JP5918859B2 (ja) | 2011-12-02 | 2016-05-18 | フェネックス ファーマシューティカルス アーゲー | オーファン核内受容体RARに関連するオーファン受容体−ガンマ(RORγ、NR1F3)活性の調整剤としての、慢性の炎症性疾患および自己免疫性疾患を治療するためのピロロカルボキサミド |
US20130190356A1 (en) | 2011-12-22 | 2013-07-25 | Genentech, Inc. | Benzyl sulfonamide derivatives as rorc modulators |
PE20150229A1 (es) * | 2012-05-31 | 2015-03-02 | Phenex Pharmaceuticals Ag | Tiazoles sustituidos por carboxamida o sulfonamida y derivados relacionados como moduladores para el receptor nuclear huerfano rory |
JO3215B1 (ar) | 2012-08-09 | 2018-03-08 | Phenex Pharmaceuticals Ag | حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy |
CN105073729A (zh) * | 2012-10-16 | 2015-11-18 | 詹森药业有限公司 | RORγt的苯基连接的喹啉基调节剂 |
EP2931281B1 (fr) * | 2012-12-12 | 2018-01-17 | Merck Sharp & Dohme Corp. | Inhibiteurs de tyrosine kinase splénique contenant une aminopyridine |
US9611254B2 (en) | 2013-06-04 | 2017-04-04 | Acturum Life Science AB | Triazole compounds and their use as gamma secretase modulators |
CN103333168B (zh) * | 2013-07-23 | 2015-08-05 | 清华大学 | 一种酰胺类化合物及其制备方法与应用 |
CN105705501B (zh) | 2013-09-09 | 2019-04-19 | 百时美施贵宝公司 | RORγ调节剂 |
US20150072890A1 (en) | 2013-09-11 | 2015-03-12 | 20/20 Gene Systems, Inc. | Methods and compositions for aiding in the detection of lung cancer |
US9725443B2 (en) | 2013-09-20 | 2017-08-08 | Bristol-Myers Squibb Company | RORγ modulators |
CA2926339A1 (fr) * | 2013-10-15 | 2015-04-23 | Janssen Pharmaceutica Nv | Modulateurs quinolinyl a liaison alkyle de roryt |
CN105636952A (zh) * | 2013-10-15 | 2016-06-01 | 詹森药业有限公司 | Rorγt的仲醇喹啉基调节剂 |
RS58650B1 (sr) | 2013-12-05 | 2019-05-31 | Lead Pharma Holding Bv | Ror gama (rory) modulatori |
JP6476205B2 (ja) | 2014-01-06 | 2019-02-27 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | RORγ修飾因子としてのヘテロ環式スルホン |
CN106061971B (zh) | 2014-01-06 | 2019-03-12 | 百时美施贵宝公司 | 吡咯烷基砜衍生物及其作为RORγ调节剂的用途 |
CN106061947B (zh) | 2014-01-06 | 2019-12-03 | 百时美施贵宝公司 | 环己基砜RORγ调节剂 |
WO2015103508A1 (fr) | 2014-01-06 | 2015-07-09 | Bristol-Myers Squibb Company | Composés sulfone carbocyclique servant de modulateurs de rorγ |
US11084784B2 (en) | 2014-03-27 | 2021-08-10 | Piramal Enterprises Limited | ROR-gamma modulators and uses thereof |
RS59752B1 (sr) | 2014-10-30 | 2020-02-28 | Janssen Pharmaceutica Nv | Amidno supstituisani tiazoli kao modulatori rorgamat |
PT3212641T (pt) | 2014-10-30 | 2019-02-11 | Janssen Pharmaceutica Nv | Tiazoles como moduladores de rorãt |
-
2014
- 2014-10-30 JO JOP/2020/0117A patent/JOP20200117A1/ar unknown
-
2015
- 2015-10-28 TW TW104135342A patent/TWI667230B/zh active
- 2015-10-28 TW TW108110613A patent/TWI705057B/zh active
- 2015-10-29 JO JOP/2015/0267A patent/JO3571B1/ar active
- 2015-10-29 MA MA40873A patent/MA40873B1/fr unknown
- 2015-10-30 UY UY0001036377A patent/UY36377A/es unknown
- 2015-10-30 CN CN201711211144.1A patent/CN107827841A/zh active Pending
- 2015-10-30 CR CR20170166A patent/CR20170166A/es unknown
- 2015-10-30 CN CN201580071983.0A patent/CN107108599A/zh active Pending
- 2015-10-30 CA CA2965512A patent/CA2965512C/fr active Active
- 2015-10-30 BR BR112017008816A patent/BR112017008816A2/pt not_active Application Discontinuation
- 2015-10-30 KR KR1020177032857A patent/KR20170127580A/ko not_active Application Discontinuation
- 2015-10-30 DK DK15802227.7T patent/DK3212643T3/da active
- 2015-10-30 EA EA201790942A patent/EA033699B1/ru not_active IP Right Cessation
- 2015-10-30 JP JP2017523358A patent/JP6998204B2/ja active Active
- 2015-10-30 LT LTEP15802227.7T patent/LT3212643T/lt unknown
- 2015-10-30 WO PCT/US2015/058193 patent/WO2016069974A1/fr active Application Filing
- 2015-10-30 US US14/927,499 patent/US9850236B2/en active Active
- 2015-10-30 AU AU2015339087A patent/AU2015339087B2/en active Active
- 2015-10-30 CR CR20170542A patent/CR20170542A/es unknown
- 2015-10-30 RS RS20190495A patent/RS58613B1/sr unknown
- 2015-10-30 ME MEP-2019-118A patent/ME03426B/fr unknown
- 2015-10-30 CN CN202110007104.5A patent/CN112979630A/zh active Pending
- 2015-10-30 PE PE2017000795A patent/PE20171649A1/es unknown
- 2015-10-30 PL PL15802227T patent/PL3212643T3/pl unknown
- 2015-10-30 EP EP15802227.7A patent/EP3212643B1/fr active Active
- 2015-10-30 EP EP18160676.5A patent/EP3354651B1/fr active Active
- 2015-10-30 PE PE2017002473A patent/PE20180250A1/es unknown
- 2015-10-30 TR TR2019/07763T patent/TR201907763T4/tr unknown
- 2015-10-30 KR KR1020177014519A patent/KR20170078750A/ko not_active Application Discontinuation
- 2015-10-30 EA EA201891562A patent/EA035998B1/ru not_active IP Right Cessation
- 2015-10-30 SG SG11201703323PA patent/SG11201703323PA/en unknown
- 2015-10-30 MX MX2017005689A patent/MX367912B/es active IP Right Grant
- 2015-10-30 BR BR122017023050A patent/BR122017023050A2/pt not_active Application Discontinuation
- 2015-10-30 AR ARP150103522A patent/AR102480A1/es unknown
- 2015-10-30 SI SI201530677T patent/SI3212643T1/sl unknown
- 2015-10-30 SG SG10201805355YA patent/SG10201805355YA/en unknown
- 2015-10-30 MX MX2018004348A patent/MX369567B/es unknown
- 2015-10-30 ES ES15802227T patent/ES2724556T3/es active Active
- 2015-10-30 PT PT15802227T patent/PT3212643T/pt unknown
- 2015-10-30 ES ES18160676T patent/ES2858503T3/es active Active
- 2015-10-30 HU HUE15802227A patent/HUE043624T2/hu unknown
-
2017
- 2017-04-23 IL IL251865A patent/IL251865A0/en unknown
- 2017-04-27 PH PH12017500800A patent/PH12017500800A1/en unknown
- 2017-04-27 CL CL2017001042A patent/CL2017001042A1/es unknown
- 2017-04-28 SV SV2017005429A patent/SV2017005429A/es unknown
- 2017-04-28 GT GT201700090A patent/GT201700090A/es unknown
- 2017-05-19 CO CONC2017/0005014A patent/CO2017005014A2/es unknown
- 2017-05-29 ZA ZA2017/03679A patent/ZA201703679B/en unknown
- 2017-05-30 EC ECIEPI201733054A patent/ECSP17033054A/es unknown
- 2017-07-31 US US15/664,673 patent/US10150762B2/en active Active
- 2017-11-08 AR ARP170103107A patent/AR110155A2/es unknown
- 2017-11-14 IL IL255648A patent/IL255648B/en active IP Right Grant
- 2017-11-20 PH PH12017502105A patent/PH12017502105A1/en unknown
- 2017-12-14 UY UY0001037517A patent/UY37517A/es unknown
-
2018
- 2018-02-09 HK HK19100569.0A patent/HK1258212A1/zh unknown
- 2018-02-16 CL CL2018000436A patent/CL2018000436A1/es unknown
- 2018-08-31 ZA ZA201805860A patent/ZA201805860B/en unknown
- 2018-08-31 ZA ZA201805861A patent/ZA201805861B/en unknown
- 2018-10-25 JP JP2018200608A patent/JP6623270B2/ja not_active Expired - Fee Related
-
2019
- 2019-01-14 AU AU2019200228A patent/AU2019200228B2/en active Active
- 2019-05-15 HR HRP20190900TT patent/HRP20190900T1/hr unknown
- 2019-06-04 CL CL2019001514A patent/CL2019001514A1/es unknown
- 2019-06-14 CY CY20191100620T patent/CY1121716T1/el unknown
-
2020
- 2020-06-18 JP JP2020104927A patent/JP2020180129A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA40873A (fr) | Alcools trifluorométhylés utilisés comme modulateurs de roryt | |
MA40863A (fr) | Thiazoles en tant que modulateurs de roryt | |
MA40865B1 (fr) | Thiazoles à substitution amide utilisés comme modulateurs de rorgammat | |
EA201590736A1 (ru) | СВЯЗАННЫЕ С МЕТИЛЕНОМ ХИНОЛИНИЛОВЫЕ МОДУЛЯТОРЫ RORγt | |
MA50240B1 (fr) | Modulateurs de la protéine régulatrice de la conductance transmembranaire de la fibrose kystique et procédés d'utilisation | |
MA43979B1 (fr) | Dérivés de 1h-indazole-3-carboxamide et composés similaires en tant qu'inhibiteurs du facteur d pour le traitement de maladies characterisés par une activité aberrante du système complémentaire, comme p.E. Troubles immunologiques | |
MA41562A1 (fr) | Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires | |
EA201590750A1 (ru) | СВЯЗАННЫЕ С ФЕНИЛОМ ХИНОЛИНИЛОВЫЕ МОДУЛЯТОРЫ RORγT | |
MA34361B1 (fr) | Dérivés de tétrahydro-pyrido-pyrimidine | |
EA201892438A1 (ru) | 6-АМИНОПИРИДИН-3-ИЛТИАЗОЛЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ RORγt | |
MA42397B1 (fr) | 4-azaindoles substituées et leur utilisation comme modulatoeurs de la récepteur glun2b | |
MA38403A1 (fr) | Nouveaux dérivés de pyrazole modulateurs specifiques de cb2 | |
MA39427A1 (fr) | Composés pyrrolidine modulateurs de gpr40 pour le traitement de maladies telles que le diabète | |
MA44037B1 (fr) | Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci | |
MA38810B1 (fr) | Inhibiteurs de rorc2 méthodes d'utilisation associées | |
MA39335A1 (fr) | Inhibiteurs mgat2 de dihydropyridinone à substitution tétrazolone | |
MX2020013297A (es) | Compuestos para el tratamiento o la prevencion de enfermedades hepaticas. | |
MA38410B1 (fr) | Composés d'azétidinyloxyphénylpyrrolidine | |
MX2022007670A (es) | Compuestos antihelminticos que comprenden una estructura de quinolina. | |
MA39253A1 (fr) | Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr | |
EA201790315A1 (ru) | Модуляторы x-рецепторов печени | |
MX2021004342A (es) | Uso de compuesto de carbamato para prevenir, aliviar o tratar neuropatía periférica diabética o neuropatía periférica inducida por quimioterapia. | |
EA202190033A1 (ru) | Соединения пиразола и имидазола для ингибирования il-17 и ror-гамма | |
MA49910B1 (fr) | Activateurs de la pyruvate kinase destinés à être utilisés dans le traitement de troubles sanguins | |
MA51534B1 (fr) | Modulateurs de la protéine régulatrice de la conductance transmembranaire de la fibrose kystique et procédés d'utilisation |